In short
This article discusses the use of Carbasalate Calcium in clinical trials, specifically in the context of stroke prevention for patients with atrial fibrillation who have recently experienced an intracerebral hemorrhage while on anticoagulation therapy. The trials aim to compare the effectiveness and safety of various antithrombotic treatments, including Carbasalate Calcium, in this high-risk patient population.
At a glance
- Study Type
- Randomized, open-label, multi-center clinical trial with masked outcome assessment
- Patient Population
- 100 adults with atrial fibrillation and recent intracerebral hemorrhage during anticoagulation treatment
- Intervention
- Apixaban vs. antiplatelet therapy (including Carbasalate Calcium) or no antithrombotic drugs
- Carbasalate Calcium Dosage
- 100 mg once daily, alone or with dipyridamole 200 mg twice daily
- Primary Outcome
- Vascular death or non-fatal stroke during follow-up
- Follow-up Duration
- 12 to 72 months
- Key Secondary Outcomes
- All-cause death, various stroke types, major hemorrhage, systemic embolism, functional outcome
What is Carbasalate Calcium?
Carbasalate calcium is a medication that belongs to a group of drugs known as antiplatelet agents. It is closely related to aspirin (acetylsalicylic acid) and works in a similar way to prevent blood clots from forming. This medication is often used in situations where doctors want to reduce the risk of blood clots but may be concerned about using stronger blood thinners.
Medical Conditions Treated
The clinical trial information suggests that carbasalate calcium is being studied for use in patients with two main conditions:
- Atrial Fibrillation (AF): This is a heart rhythm disorder where the upper chambers of the heart beat irregularly. It can increase the risk of blood clots forming in the heart.
- Cerebral Hemorrhage: Also known as an intracerebral hemorrhage (ICH), this is a type of stroke caused by bleeding within the brain tissue.
Carbasalate calcium is being considered as a treatment option for patients who have both atrial fibrillation and a history of cerebral hemorrhage while on anticoagulant therapy (stronger blood thinners).
Usage in Clinical Trial
In the clinical trial described (NCT02565693), carbasalate calcium is being studied as one of the possible treatment options for patients who have experienced a brain bleed (intracerebral hemorrhage) while taking anticoagulants for atrial fibrillation. The trial is comparing different approaches to prevent future strokes in these high-risk patients:
- Using a newer anticoagulant called apixaban
- Using antiplatelet drugs like carbasalate calcium
- Not using any blood-thinning medications
Dosage Information
According to the trial information, when carbasalate calcium is used, the dosage is 100 mg once daily. However, it's important to note that dosages can vary depending on individual patient factors, and you should always follow your doctor's specific instructions.
Comparison with Other Treatments
The clinical trial compares carbasalate calcium with other treatment options:
- Apixaban: This is a newer type of anticoagulant that might be more effective at preventing strokes but could potentially increase bleeding risk.
- Other antiplatelet drugs: These include aspirin, clopidogrel, and dipyridamole. They work similarly to carbasalate calcium but may have slightly different effects or side effect profiles.
- No antithrombotic treatment: This means not using any blood-thinning medications, which might reduce bleeding risk but could increase the risk of blood clots.
Potential Benefits and Risks
The potential benefits of using carbasalate calcium in this context include:
- Reducing the risk of ischemic stroke (strokes caused by blood clots)
- Potentially lower risk of bleeding compared to stronger anticoagulants
However, there are also potential risks to consider:
- It may not be as effective as stronger anticoagulants in preventing strokes in patients with atrial fibrillation
- There is still a risk of bleeding, including recurrent intracerebral hemorrhage
The clinical trial aims to better understand these benefits and risks to help guide future treatment decisions for patients in this complex situation.